Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in ...

Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering ...

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic ...

The most notable development for Verastem has been the U.S. Food and Drug Administration (FDA) approval of its drug Avmapki Fakzynja Co-Pack (Av-Fak) for the treatment of low-grade serous ovarian ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Advanced Solid Tumors To supplement Verastem Oncology’s condensed consolidated financial statements, which are prepared and presented in ...

The Needham, Massachusetts-based company said it had a loss of 96 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

NEEDHAM, Mass. (AP) — NEEDHAM, Mass. (AP) — Verastem Inc. (VSTM) on Tuesday reported a loss of $52.1 million in its first quarter. The Needham, Massachusetts-based company said it had a loss ...